



AstraZeneca Pharma - June-23 - Results Review

Quarter Highlights

Revenue Flat

Profit Up




Presenter :

TheNumberTalks - By Rishika

AstraZeneca Pharma - June-23 - Results Review

Amt. in Cr.

Quarterly Revenue




Change%	4%	14%	6%	2%
---------	----	-----	----	----

Revenue of Jun 23 has increased by 4%, as compared to previous quarter revenue Mar 23. Revenue has increased from 284.7 Cr. to 295.47 Cr.

Revenue of Jun 23 has increased by 27%, as compared to revenue of preceding quarter of last financial year in Jun 22. Revenue has increased from 232.33 Cr. to 295.47 Cr.

Annual Revenue




Change%	24%	-1%	-2%	14%
---------	-----	-----	-----	-----

Revenue of Mar 23 has increased by 24%, as compared to previous financial year in Mar 22. Revenue has increased from 805.6 Cr. to 1002.97 Cr.

AstraZeneca Pharma - June-23 - Results Review

Amt. in Cr.

Quarterly Net Profit (B4 Except. Items)




NP B4 Exp.%	24%	22%	16%	19%	12%
NPAT	18%	6%	12%	14%	9%

Net Profit Margin AFTER TAX of the Company when compared to previous quarter has increased from 6.07% to 18.26%.

Net Profit Margin AFTER TAX of the Company when compared to preceding quarter of previous financial year has increased from 8.67% to 18.26%.

Annual Net Profit (B4 Except. items)




NP B4 Excpt %	17%	10%	16%	14%	10%
NPAT	10%	8%	11%	9%	7%

Annual Net Profit Margin AFTER TAX of the Company has Increase from 7.65% to 9.9%.


This is an Increase of 2.25% when compared to previous financial years margin. In absolute terms Profit has increase from 62 Cr. to 99 Cr.

AstraZeneca Pharma - June-23 - Results Review

Quarter Cost Composition



Quarter Cost Comparison




Amt. in Cr.

Costs	Q-Q Change	Y-Y Change
Revenue	11 (4%)	63 (27%)
COGS	12 (12%)	27 (33%)
Employee Cost	-12 (-18%)	-13 (-20%)
Other Expense	3 (5%)	10 (19%)
Finance Cost	0 (74%)	0 (-18%)


EBITDA Margin

Jun 2023	Mar 2023
22.79%	21.02%

Annual Cost Composition



Annual Cost Comparison



AstraZeneca Pharma - June-23 - Results Review

22.61%

Return on Equity

37.22%

Return on Capital
Employed

NA

Share Price Change
1 Month

5%

CAGR - Revenue
Past 4 Years

Share Price Change
3 Month

2%

CAGR - Profit
Past 4 Years

Share Price Change
1 Year

100.46

Company PE

44.11

Industry PE

NA

Share Price Change
2 Year

Particulars	Quarterly (Rs. In Cr.)			
	Jun 2023	Mar 2023	Dec 2022	Jun 2022
Revenue	295	285	250	232
Cost of Sales	111	99	91	83
Employee Cost	55	67	63	68
Other Expenses	63	59	59	53
Earning Before Depreciation & Tax (EBITDA)	67	60	37	28
Depreciation	4	4	4	5
Interest Expense	0	0	0	0
Other Income	8	8	7	4
Net Profit Before Exceptional Items	71	64	39	27
Exception Items	0	40	0	0
Net Profit Before Tax	71	23	39	27
Taxes	18	6	10	7
Net Profit After Tax	54	17	29	20
Gross Margin %	62.6%	65.4%	63.4%	64.1%
EBITDA %	22.8%	21.0%	14.6%	12.0%
NP Before Exception Items %	24.20%	22.31%	15.79%	11.75%
Net Profit After Tax %	18.26%	6.07%	11.73%	8.67%

Thank you for Watching,

“The NumberTalks - By Rishika”

